

Important: Read carefully!

Elicasal™

mometasone furoate 0.1% w/w, salicylic acid 5% w/w

COMPOSITION:

Ointment

Each gram of Elicasal™ ointment contains active compound mometasone furoate 1 mg and salicylic acid 50 mg in suitable ointment base.

INDICATIONS:

Mometasone furoate belongs to a group of medicines called corticosteroids or steroids as they are simply known. Mometasone is a strongly acting glucocorticoid with anti-inflammatory and antipruritic effect. Salicylic acid helps to remove dry and scaling skin. Salicylic acid also increases the uptake of mometasone.

Elicasal™ is used to treat psoriasis, especially in case of intensive scaling.

DOSAGE AND ADMINISTRATION:

Apply a thin film of Elicasal™ to the affected skin areas twice or once daily.

PHARMACOLOGY:

Mometasone is a synthetic corticosteroid, exhibits anti-inflammatory, antipruritic and vasoconstrictive properties. Topical salicylic acid softens Keratin, loosens cornfield epithelium and desquates the epidermis.

PRECAUTION:

Avoid ointment on eyes or on mucous membranes. Elicasal™ is not to be used in the face without prescription by your doctor. Treatment during longer periods and on large body surface areas, on wounds and wounded skin, and in the armpits and groins should be avoided. The ointment should not be used under bandages or similar. Glucocorticoids can mask, trigger or worsen skin infections. If you develop skin infections while using this ointment, your doctor will give you an appropriate treatment for fungal or bacterial infections. If you do not respond to treatment, please discontinue Elicasal™ until the infection is under control. Contact your doctor if irritation, including excessive dryness develops. The treatment might need to be discontinued and appropriate therapy instituted. Use of topical corticosteroid in children should be limited to the least amount compatible with an effective therapeutic regimen.

Since safe use of mometasone furoate 0.1% in pregnant women has not been established, topical corticosteroids should be used during pregnancy only if the potential benefit justifies potential risk to the fetus. It is not known whether topical administrations of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in the breast milk, thus a decision should be made whether to discontinue nursing or to discontinue the drug taking into account the importance of the drug to the mother. Excessive prolonged use of topical corticosteroid can suppress HPA axis resulting in secondary adrenal insufficiency and Cushing's syndrome.

CONTRAINDICATIONS :

Do not use Elicasal™ ointment if you are allergic (hypersensitive) to mometasone furoate, salicylic acid or any of the other ingredients of Elicasal™ ointment. If you have a bacterial infection (e.g. pyoderma [pus-producing skin disease], syphilis, tuberculosis), viral infection (e.g. herpes simplex, chicken pox, shingles, warts, genital warts, molluscum contagiosum), fungal infection (e.g. dermatophytosis, yeast) and/or parasitic infection, unless the causes of these diseases are being treated as well. In the final trimester of a pregnancy.

ADVERSE REACTIONS:

Local adverse reactions reported very rarely with mometasone furoate 0.1% ointment include burning, pruritus, stinging and signs of skin atrophy.

STORAGE : Store below 30 °C.

PRESENTATION :

Elicasal™ ointment, 30g in aluminium collapsible tube.

THIS IS A MEDICAMENT

- Medicament is a product that affects your health, and its consumption contrary to instructions is dangerous for you.
- Follow strictly the doctor's prescription, the method of use and the instructions of the pharmacist who sold the medicament.
- The doctor and the pharmacist are experts in medicine, its benefits and risks.
- Do not by yourself interrupt the period of treatment prescribed.
- Do not repeat the same prescription without consulting your doctor.

Keep medicament out of reach of children

Council of Arab Health Ministers & Union of Arab Pharmacists



Elicasal™ is a quality product manufactured by:



جمجوم فارما
Jamjoom Pharma

P.O.Box 6267 Jeddah - 21442 - Saudi Arabia

32171133 - Rev. 08S/18-02-12